Cagrilintide 10vials/box

Product Basic Information

Full Name: Cagrilintide

Category: Long-acting amylin receptor agonist synthetic peptide

Form: Sterile lyophilized peptide powder, individually packaged in vials

Applicable Research Directions: Weight regulation, appetite suppression, energy homeostasis, type 2 diabetes, hepatic lipid metabolism, gastrointestinal emptying-related in vitro cell/animal experimental reagents

II. Mechanism of Action

Central Appetite Suppression: Acts on the hypothalamus feeding center in the brain, reducing hunger signals, increasing satiety, and reducing calorie intake over a long period;

Delayed Gastric Emptying: Slows the rate of gastric emptying, stabilizes postprandial blood glucose fluctuations, and reduces postprandial insulin spikes;

Pancreatic Islet Synergistic Regulation: Inhibits excessive glucagon secretion, reduces hepatic glucose output, and works in conjunction with GLP-1 Complementary peptide pathways; Body fat homeostasis regulation: Downregulates visceral fat accumulation signals, improves overall energy balance, and reduces blood lipids and liver lipid deposition; Long-lasting modification characteristics: The peptide structure is modified with fatty acid side chains, resulting in strong albumin binding capacity and a significantly longer duration of action in in vitro cell systems compared to natural amylin.

III. Core Scientific Efficacy

Weight loss metabolic model: Used for in vitro research on the mechanisms of obesity and high-calorie-induced fat accumulation; Glucose metabolism intervention experiments: Suitable for cell-controlled experiments related to insulin resistance, type 2 diabetes, and postprandial hyperglycemia; Liver lipid metabolism support: Can be combined with LC120, Pancragen, and Livagen to construct a combined research system for fat reduction and liver protection; Gastrointestinal motility research: Explores the regulatory pathways of gastric emptying and intestinal nutrient absorption; Combination therapy research: Often combined with GLP-1/GCGR dual agonists such as Semaglutide, Survodutide, and Mazdutide to compare the differences in metabolic regulation between single drugs and combination therapy. IV. Reconstitution and Storage Specifications

Reconstitution Solvents: Sterile water for injection, 0.6% acetic acid aqueous solution, and physiological saline can all be used to prepare experimental working solutions. Mix gently; vigorous shaking is prohibited.

Storage Requirements

Unopened lyophilized powder: Store at 2-8℃ protected from light and sealed. Freezing is strictly prohibited, as it will damage the fatty acid modification structure and cause activity loss.

Reconstituted liquid: Store at 4℃ protected from light.